The global Hemoglobin Testing Devices Market was valued at USD 4065.44 Million in 2021 and is expected to reach USD 6195.63 Million by the end of 2028, growing at a CAGR of 5.92% during the forecast period of 2022-2028. The hemoglobin testing devices market is cast to notice substantial growth because of the rising prevalence of anemia cases. Anemia is a prominent public health issue that influences developed and developing nations. According to statistics, nearly 1.6 billion people are suffering from anemia globally. As a result, several federal bodies across the globe have commenced executing state-wide initiatives to spread attention about the ill consequences of anemia. Such endeavors could hugely help the hemoglobin testing devices market in the future.
Hemoglobin is a known iron-based metalloproteinase in the red blood cells of humans. Its key procedure is to transport oxygen from the lungs to the rest of the body. A hemoglobin test estimates the level of hemoglobin or counts the red blood cells (RBC) in blood. These tests are operated extensively by physicians and doctors to diagnose any therapeutic conditions in the patient. If the test results depict a lower hemoglobin concentration in the bloodstream, it implies higher chances of patients being anemic. The growing prevalence of anemia across the globe is a major factor augmenting hemoglobin testing devices industry growth.
An increasing majority of chronic diseases such as anemia and diabetes are key elements causing the global hemoglobin testing market. The prevalence of diabetes is presently being catalyzed by increasingly aging people, poor dietary habits, sedentary lifestyles and increasing levels of obesity. Patients with diabetes must undergo tests to regularly calculate blood glucose and HbA1c levels, pushing the demand for such tests. Moreover, elements such as promising repayment of hemoglobin testing under different health insurance policies also catalyze the market’s growth. Similarly, factors such as enhancing health infrastructure, increasing per capita expenditure on health care, increasing awareness for blood-related ailments, aging population, technological improvements, etc., are also estimated to drive the global hemoglobin testing market.
Increasing the organization of clinics across growing and developed economies could drive the demand for hemoglobin testing devices across clinical establishments. Earlier in 2018, the clinic segment had recorded a high revenue share. Shifting inclination towards diagnostic clinics due to the increasing presence of state-of-the-art facilities could enhance the industry landscape.
Increasing technological improvements in hemoglobin testing analyzers are another major element boosting industry growth. The traditional hematology analyzers have a few restrictions while differentiating cellular elements due to a single histogram per module. However, modern analyzers are incorporated with novel technology to gauge data from multiple histograms, thereby overcoming the limitations of traditional analyzers. Hence, such technological advancements will improve the test outcome and boost product demand and opportunities across the forecast years.
The increase in the classes of costs associated with the medical devices and rise in the problems regarding the increased maintenance costs are anticipated to curb the growth of the hemoglobin testing device market, whereas the lack of detection of other molecular components other than hemoglobin levels with this test can challenge the growth of the hemoglobin testing device market.
Sampling mistakes during the blood testing by the user and a shorter life span may also restrain the hemoglobin testing systems market.
Before the covid-19 period, the rising number of FDA approvals for novel hemoglobin tests and analyzers will considerably augment market growth. For instance, in February 2019, HemoCue, a subsidiary of Danaher, announced that it received clearance from U.S. FDA for its point of care testing product. Moreover, increasing awareness about the blood testing program and blood donation camps is expected to fuel the growth of the hemoglobin testing device market during the pandemic outbreak.
During the Covid-19 period, many patients were forced to shift their routine care from in-person visits to online or telehealth consultations. Therefore, HbA1c testing noticed a harsh impact, with point-of-care testing volumes dropping by nearly 80% during the pandemic period. Given this considerable reduction in HbA1c testing volume, the hemoglobin testing device market, in general, may have noticed certain roadblocks during the initial months of the pandemic. However, since regular HbA1c and blood glucose level testing is a critical aspect of care for diabetic patients, steps have been made to enhance hemoglobin testing in recent months. These include developing remote blood sampling programs and allowing patients to collect blood samples at home and send them for laboratory examination. Execution of such programs will not only help improve HbA1c testing during the pandemic.
After the covid-19 period, due to fear of infection, now most patients choose home care testing over laboratories; there is growth in the market for direct-to-consumer testing devices, which is a major factor driving the market growth. Moreover, the emergence of progressive techniques has enhanced the ease of testing devices and provides quick test results. Hence, the development of advanced hemoglobin testing devices is further expected to boost the market growth after the covid-19 period.
Based on technology, the global hemoglobin testing devices market is segmented into Chromatography, Immunoassay and Others. Chromatography is estimated to increase at the highest CAGR during the forecast period. Chromatography-based tests are free from complexities such as common interferences of non-glycation transformations, hemoglobin variants and storage-related Hemi chromes. Other advantages of the chromatography technique include high specificity, accuracy, simplicity and cost-effectiveness, thus driving segmental growth.
Based on End-user, the global hemoglobin testing devices market is segmented into Hospitals, Research Centers, Laboratories and others. Hospitals may share the promising growth over the forecast period, as the number of people seeing the hospital to diagnose different types of disease, so for accurate disease diagnosis, doctors mainly refer to the hemoglobin count before treatment starts. Diagnostic laboratories show the second prevailing market for hemoglobin test systems since diagnostic laboratories are anticipated to enhance the demand for hemoglobin test systems in the coming years due to new diagnostic technologies and significant development in the market for hemoglobin test systems.
Based on region, the global hemoglobin testing devices market is segmented into North America, Europe, Asia-Pacific, South America and The Middle East & Africa. North America holds the highest share in the global hemoglobin testing devices market Due to the increased number of blood bank faculties and diagnostic centers with a good set-up. Due to the growing awareness of blood-related problems and the growing market for novel diagnostic devices in hospitals and laboratories, Europe’s area is anticipated to show expanded demand for hemoglobin testing devices. Asia-Pacific is the fastest-growing market for hemoglobin testing devices due to rising investment in research and growth in counties such as India, China, and Japan by local medical device corporations. Countries like South America and Middle East Africa are the least opportunities market for hemoglobin testing devices due to a lack of awareness and inadequacy of serious blood-related difficulties among the population.
The companies include Abbott Laboratories, ACON Laboratories, Alere, Bayer Medical Care, Bio-Rad Laboratories, Danaher, EKF Diagnostics Holdings, F. Hoffmann-La Roche, Siemens Healthcare, Thermo Fisher Scientific and other prominent players in the global hemoglobin testing devices market.
Key Stakeholders
| Report Attribute | Details |
|---|---|
| Revenue in 2021 | USD 4065.44 Million |
| The revenue forecast in 2028 | USD 6195.63 Million |
| Growth Rate | CAGR of 5.92 % from 2022 to 2028. |
| Historical data | 2017 – 2020 |
| Base Year | 2021 |
| Forecast period | 2022 – 2028 |
| Region covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Key companies Profiled | Abbott Laboratories, ACON Laboratories, Alere, Bayer Medical Care, Bio-Rad Laboratories, Danaher, EKF Diagnostics Holdings, F. Hoffmann-La Roche, Siemens Healthcare and Thermo Fisher Scientific are the key players. |
By Technology
By End-User
By Region
Hemoglobin is a known iron-based metalloproteinase in the red blood cells of humans. Its key procedure is to transport oxygen from the lungs to the rest of the body. A hemoglobin test estimates the level of hemoglobin or counts the red blood cells (RBC) in blood. These tests are operated extensively by physicians and doctors to diagnose any therapeutic conditions in the patient.
An increasing majority of chronic diseases such as anemia and diabetes are key elements causing the global hemoglobin testing market. The prevalence of diabetes is presently being catalyzed by increasingly aging people, poor dietary habits, sedentary lifestyles and increasing levels of obesity. Patients with diabetes must undergo tests to regularly calculate blood glucose and HbA1c levels, pushing the demand for such tests.
During the Covid-19 period, many patients were forced to shift their routine care from in-person visits to online or telehealth consultations. Therefore, HbA1c testing noticed a harsh impact, with point-of-care testing volumes dropping by nearly 80% during the pandemic period.
Abbott Laboratories, ACON Laboratories, Alere, Bayer Medical Care, Bio-Rad Laboratories, Danaher, EKF Diagnostics Holdings, F. Hoffmann-La Roche, Siemens Healthcare and Thermo Fisher Scientific are the key players in the global hemoglobin testing device market.
North America holds the highest share in the global hemoglobin testing devices market, Due to the growing awareness of blood-related problems and the growing market for novel diagnostic devices in hospitals and laboratories.
Analyst support
After evaluating your requirements and addressing your technical problems, the expert analyst will resolve your query directly.
Customer satisfaction
According to your needs, our expert team will assist you with the capabilities, services, and proper research needs to be required and customize the report accordingly.
Inimitable expertise
Our expert team will create unrivaled reviews to provide you with a deep understanding of the reports.
Assured quality
We have created a systematic way to determine standards and satisfy your expectations.
Instant delivery
Unlike others, we provide you a great deal of instant delivery in the form of PDF/PPT/Word Doc directly to your email address within 24 hours after receiving full payment.
Privacy policy
We understand the inkling of your privacy, we will never misuse your email address.
Custom research service
We are giving you an opportunity through which you can directly ask our expert analyst to customize an exclusive study of the report to serve your research needs.
Quality & accuracy
We provide you with the accurate quality of the customized study of an exclusive report according to your research need.
Data visualization
As the business world’s growing faster every day, we understand the value of data management. We will create the reports by keeping all the visual data sets and metrics in the charts.
Information security
We truly respect your privacy and promise to keep your personal and confidential information safe and secure.